Non-smoking Clinical Trial
— REBOC2Official title:
Investigation of the Effects of Daily Nitrate Consumption on Oral Bacteria Composition, Blood Pressure and Vascular Functio
Verified date | April 2024 |
Source | University of Reading |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Diseases of the heart and blood vessels, including raised blood pressure, are one of the leading causes of death worldwide. Higher intakes of dietary nitrate, found abundantly in root vegetables such as beetroot, have been shown to have health benefits including lowering blood pressure and improving the elasticity of blood vessels. Bacteria which reside in the mouth and those in the gastrointestinal tract play an important role in converting dietary nitrate to nitrite and nitric oxide (a chemical which promotes the relaxation of blood vessels). In particular, removal of oral bacteria by using antiseptic mouthwash is accompanied by an increase in blood pressure in subjects with normal blood pressure, even after consuming nitrate-rich foods. To date, very little is known about the role of these oral bacteria in the control of blood pressure, and if there are any differences in bacterial composition between individuals.
Status | Completed |
Enrollment | 28 |
Est. completion date | December 1, 2021 |
Est. primary completion date | December 1, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 64 Years |
Eligibility | Inclusion Criteria: Male and female; - A signed consent form; - Blood pressure <140/90 mm Hg; - BMI range 18.5 - 39.9 kg/m2; - Age 18-64 years; - Non-smoking; - Not taking blood pressure lowering medication or using medications known to influence vascular function such as a glyceryl trinitrate (GTN) spray; - No recent (within 3 months) or current use of antibiotics. Exclusion criteria are: Diagnosed with a chronic illness; - Anaemia defined as a haemoglobin < 115 g/l for women and <130 g/l for men; - Individuals with food allergies or allergies to medicated mouthwash or ingredients in the oral products; - Requirements to take long-term medication active on the oral cavity including prebiotics and probiotics or have taken antibiotics within the last 3 months; - Gingivitis diagnosis, or periodontal disease or chronic oral complaints or existing oral pathology. - Less than four natural (enamel) buccal surfaces of upper molars available; - Presence of fixed or removable oral appliances (e.g., dentures, orthodontic wires); xerostomia (a persistent dry mouth) diagnosis; - Current smoker; - Already participating in a dietary intervention study or clinical trial; - Excessive alcohol consumption (> 14 units/wk); - Females who are pregnant or lactating; - Individuals not willing to give up using mouthwash or change their dental hygiene routine. Regular consumption or use of xylitol-based products such as toothpaste and chewing gum. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Hugh Sinclair Unit of Human Nutrition, Department of Food and Nutritional Sciences, University of Reading | Reading | Berkshire |
Lead Sponsor | Collaborator |
---|---|
University of Reading | Saudi Cultural Bureau |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in blood pressure measure | Systolic blood pressure, diastolic blood pressure and pulse pressure | Before and after each 8 week intervention | |
Primary | Change in oral bacteria composition | Oral bacteria composition determined using next generation sequencing. | Before and after each 8 week intervention | |
Secondary | Change in vascular reactivity | Laser Doppler Imaging with iontophoresis. | Before and after each 8 week intervention | |
Secondary | Change in Nox concentrations in serum, urine and saliva | Nitrate and nitrite concentrations will be determined using high performance liquid chromatography in plasma, urine and saliva. Nitric oxide will be calculated as the sum of nitrate and nitrite concentrations.
Creatinine will be measured in the urine samples to normalise the nitrate and nitrite concentrations in urine for hydration status. |
Before and after each 8 week intervention | |
Secondary | Change in gut bacteria composition | Stool sample will be analysed to determine composition using next generation sequencing will be used to find the differences between treatments. | Before and after each 8 week intervention | |
Secondary | Change in fasting lipid profile | Total cholesterol, HDL-C, and triacylglycerol will be measured using a clinical chemistry analyser. LDL-C will be calculated using the Friedewald formula. | Before and after each 8 week intervention | |
Secondary | Change in C-reactive protein | C-reactive protein will be measured using a clinical chemistry analyser | Before and after each 8 week intervention | |
Secondary | Change in endothelial function | Pulse wave analysis will be measured using Mobil-O-Graph | Before and after each 8 week intervention | |
Secondary | Change in body weight | Body weight will be measured using a Tanita scale | Before and after each 8 week intervention | |
Secondary | Height measurement | Height will be measured using a stadiometer | Before the intervention | |
Secondary | Change in body mass index | Body mass index will be calculated from the body weight and height measurement | Before and after each 8 week intervention | |
Secondary | Change in insulin | Insulin levels will be measured by ELISA | Before and after each 8 week intervention | |
Secondary | Change in glucose | Glucose levels will be measured using a clinical chemistry analyser | Before and after each 8 week intervention | |
Secondary | Change in insulin sensitivity | Glucose and insulin measurements will be used to calculate the homeostatic model assessment of insulin resistance (HOMA-IR) | Before and after each 8 week intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03068962 -
Examination of the Distribution of Nitrate Reducing Bacteria in the Human Oral Cavity
|
N/A | |
Completed |
NCT01465880 -
Smoking Research Study
|
N/A | |
Completed |
NCT00694044 -
Evaluation of Varenicline Safety, Tolerability, Pharmacokinetics and Pro-Cognitive Effects in Healthy Elderly Non-Smoking Subjects
|
Phase 1 |